Data from the multi-center phase II trial of NX-1207, Nymox’s lead drug candidate for the treatment of benign prostatic hyperplasia (BPH), has led the company to suggest it has a potential first-line treatment for BPH.
In two completed US trials the drug has shown highly significant efficacy without significant side effects. The company’s large phase II trial is expected to be completed later this year.
During the trials to date, participants treated with NX-1207 showed a statistically significant overall mean symptom improvement and a statistically significant shrinkage in prostate size. There were no significant adverse side effects from the drug in these trials. Furthermore, subjects followed for up to two years post-treatment showed even further statistically significant symptom improvement.
According to Nymox, BPH afflicts approximately half of all men over the age of 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.